201 related articles for article (PubMed ID: 15919240)
1. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency.
Kreuz W; Meili E; Peter-Salonen K; Haertel S; Devay J; Krzensk U; Egbring R
Transfus Apher Sci; 2005 Jun; 32(3):247-53. PubMed ID: 15919240
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic properties of a pasteurised fibrinogen concentrate.
Kreuz W; Meili E; Peter-Salonen K; Dobrkovská A; Devay J; Haertel S; Krzensk U; Egbring R
Transfus Apher Sci; 2005 Jun; 32(3):239-46. PubMed ID: 15919241
[TBL] [Abstract][Full Text] [Related]
3. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency.
Peyvandi F
Thromb Res; 2009 Dec; 124 Suppl 2():S9-11. PubMed ID: 20109654
[TBL] [Abstract][Full Text] [Related]
4. Fibrinogen concentrate for acquired hypofibrinogenaemic states.
Weinkove R; Rangarajan S
Transfus Med; 2008 Jun; 18(3):151-7. PubMed ID: 18598277
[TBL] [Abstract][Full Text] [Related]
5. Retrochorionic hematoma in congenital afibrinogenemia: resolution with fibrinogen concentrate infusions.
Aygören-Pürsün E; Martinez Saguer I; Rusicke E; Louwen F; Geka F; Ivaskevicius V; Oldenburg J; Klingebiel T; Kreuz W
Am J Hematol; 2007 Apr; 82(4):317-20. PubMed ID: 17034026
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen concentrate--a potential universal hemostatic agent.
Fenger-Eriksen C; Ingerslev J; Sørensen B
Expert Opin Biol Ther; 2009 Oct; 9(10):1325-33. PubMed ID: 19645632
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and treatment of congenital fibrinogen deficiency.
Peyvandi F
Thromb Res; 2012 Dec; 130 Suppl 2():S7-11. PubMed ID: 23439004
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
Levi M; Toh CH; Thachil J; Watson HG
Br J Haematol; 2009 Apr; 145(1):24-33. PubMed ID: 19222477
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency.
Djambas Khayat C; El Khorassani M; Lambert T; Gay V; Barthez-Toullec M; Lamazure J; Bellon A; Henriet C; Bridey F; Négrier C
J Thromb Haemost; 2019 Apr; 17(4):635-644. PubMed ID: 30661302
[TBL] [Abstract][Full Text] [Related]
10. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
11. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery.
Rahe-Meyer N; Solomon C; Winterhalter M; Piepenbrock S; Tanaka K; Haverich A; Pichlmaier M
J Thorac Cardiovasc Surg; 2009 Sep; 138(3):694-702. PubMed ID: 19698858
[TBL] [Abstract][Full Text] [Related]
12. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register.
Weiss G; Lison S; Glaser M; Herberger S; Johanning K; Strasser T; Huber T; Spannagl M; Heindl B
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):727-34. PubMed ID: 22024795
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous intracranial bleeding in two patients with congenital afibrinogenaemia and the role of replacement therapy.
Parameswaran R; Dickinson JP; de Lord S; Keeling DM; Colvin BT
Haemophilia; 2000 Nov; 6(6):705-8. PubMed ID: 11122402
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fibrinogen concentrate for on-demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency.
Djambas Khayat C; Lohade S; D'Souza F; Shamanur LG; Zekavat OR; Kruzhkova I; Schwartz B; Solomon C; Knaub S; Peyvandi F
Haemophilia; 2021 Mar; 27(2):283-292. PubMed ID: 33326665
[TBL] [Abstract][Full Text] [Related]
15. [Fibrinogen substitution. Use in the treatment of bleeding due to lack of fibrinogen].
Ingerslev J; Sørensen B
Ugeskr Laeger; 2005 Jun; 167(25-31):2759-61. PubMed ID: 16014260
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial.
Lissitchkov T; Madan B; Djambas Khayat C; Zozulya N; Ross C; Karimi M; Kavakli K; De Angulo GR; Almomen A; Schwartz BA; Solomon C; Knaub S; Peyvandi F
Transfusion; 2018 Feb; 58(2):413-422. PubMed ID: 29194665
[TBL] [Abstract][Full Text] [Related]
17. Congenital afibrinogenaemia.
Mehta S; Mehta SR; Malhotra H; Sharma UB; Varma AR
J Assoc Physicians India; 1989 Oct; 37(10):668-9. PubMed ID: 2490152
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Bor MV
Ugeskr Laeger; 2024 Jan; 186(1):. PubMed ID: 38235772
[TBL] [Abstract][Full Text] [Related]
19. Cryoprecipitate: no longer the best therapeutic choice in congenital fibrinogen disorders?
Bevan DH
Thromb Res; 2009 Dec; 124 Suppl 2():S12-6. PubMed ID: 20109651
[TBL] [Abstract][Full Text] [Related]
20. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
